COPD clinical trials in Dallas, TX
13 studies for COPD are looking for participants at sites in and around Dallas (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
RecruitingPhase 3
- GC2501 Study Site 109, Dallas
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
RecruitingPhase 2
- Research Site, Dallas
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
RecruitingPhase 3
- IntraCare- Site Number : 8400034, Dallas
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
RecruitingPhase 2/3
- Alina Clinical Trials, LLC., Dallas
- Baylor Scott & White Advanced Lung Disease Specialists, Dallas
- Baylor University Medical Center (Research Office), Dallas
- and 1 more
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
RecruitingPhase 3
- Texas Health Presbyterian Hospital Dallas- Site Number : 8400032, Dallas
STRIVE Post-Market Registry Study
RecruitingObservational study
- Baylor Scott & White Research Institute, Dallas
- University of Texas Southwestern, Dallas
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
RecruitingPhase 3
- GSK Investigational Site, Dallas
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation
RecruitingPhase 3
- GSK Investigational Site, Dallas
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
RecruitingPhase 3
- Research Site, Dallas
An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema
Recruiting
- University of Texas Southwestern, Dallas
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
RecruitingPhase 3
- Research Site, Dallas
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
RecruitingPhase 3
- GSK Investigational Site, Dallas
Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
RecruitingObservational study
- Liver Center of Texas, Dallas
About COPD
COPD (chronic obstructive pulmonary disease) makes it hard for you to breathe. At first symptoms are mild, but they usually become more severe. Learn more.
More about COPD on MedlinePlus
COPD trials in other cities
- Philadelphia, PA26 studies
- Miami, FL20 studies
- Houston, TX18 studies
- Birmingham, AL17 studies
- Baltimore, MD16 studies
- Boston, MA15 studies
- Orlando, FL15 studies
- Chicago, IL15 studies
- New York City, NY12 studies
- Pittsburgh, PA11 studies
- Winston-Salem, NC11 studies
- Hialeah, FL10 studies
Other studies in Dallas
- Breast Cancer54 studies
- Non-Small Cell Lung Cancer53 studies
- Metastatic Cancer44 studies
- Heart Failure42 studies
- Cancer (all types)40 studies
- Prostate Cancer39 studies
- Colorectal Cancer34 studies
- Obesity33 studies
- Ovarian Cancer31 studies
- Bladder Cancer27 studies
- Lung Cancer26 studies
- Endometrial Cancer25 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.